These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32343721)

  • 1. Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT).
    Nakano D; Kawaguchi T; Iwamoto H; Hayakawa M; Koga H; Torimura T
    PLoS One; 2020; 15(4):e0232283. PubMed ID: 32343721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation.
    Hung MH; Chen YL; Chen LJ; Chu PY; Hsieh FS; Tsai MH; Shih CT; Chao TI; Huang CY; Chen KF
    Cell Death Dis; 2019 May; 10(6):420. PubMed ID: 31142735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
    Kaji K; Nishimura N; Seki K; Sato S; Saikawa S; Nakanishi K; Furukawa M; Kawaratani H; Kitade M; Moriya K; Namisaki T; Yoshiji H
    Int J Cancer; 2018 Apr; 142(8):1712-1722. PubMed ID: 29205334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canagliflozin regulates metabolic reprogramming in diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns.
    Shao M; Chen D; Wang Q; Guo F; Wei F; Zhang W; Gan T; Luo Y; Fan X; Du P; Liu Y; Ma X; Ren G; Song Y; Zhao Y; Qin G
    Diabetologia; 2024 Apr; 67(4):738-754. PubMed ID: 38236410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism.
    Zügner E; Yang HC; Kotzbeck P; Boulgaropoulos B; Sourij H; Hagvall S; Elmore CS; Esterline R; Moosmang S; Oscarsson J; Pieber TR; Peng XR; Magnes C
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canagliflozin impairs blood reperfusion of ischaemic lower limb partially by inhibiting the retention and paracrine function of bone marrow derived mesenchymal stem cells.
    Lin Y; Nan J; Shen J; Lv X; Chen X; Lu X; Zhang C; Xiang P; Wang Z; Li Z
    EBioMedicine; 2020 Feb; 52():102637. PubMed ID: 31981975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
    Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells.
    Satou R; Cypress MW; Woods TC; Katsurada A; Dugas CM; Fonseca VA; Navar LG
    Am J Physiol Renal Physiol; 2020 Jan; 318(1):F67-F75. PubMed ID: 31682172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells.
    Uthman L; Kuschma M; Römer G; Boomsma M; Kessler J; Hermanides J; Hollmann MW; Preckel B; Zuurbier CJ; Weber NC
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1083-1094. PubMed ID: 33048256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effect of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice.
    Otsuka H; Yokomizo H; Nakamura S; Izumi Y; Takahashi M; Obara S; Nakao M; Ikeda Y; Sato N; Sakamoto R; Miyachi Y; Miyazawa T; Bamba T; Ogawa Y
    Biochem J; 2022 Feb; 479(3):425-444. PubMed ID: 35048967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours.
    Nwosu ZC; Battello N; Rothley M; Piorońska W; Sitek B; Ebert MP; Hofmann U; Sleeman J; Wölfl S; Meyer C; Megger DA; Dooley S
    J Exp Clin Cancer Res; 2018 Sep; 37(1):211. PubMed ID: 30176945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canagliflozin reduces chemoresistance in hepatocellular carcinoma through PKM2-c-Myc complex-mediated glutamine starvation.
    Zeng Y; Jiang H; Zhang X; Xu J; Wu X; Xu Q; Cai W; Ying H; Zhou R; Ding Y; Ying K; Song X; Chen Z; Zeng L; Zhao L; Yu F
    Free Radic Biol Med; 2023 Nov; 208():571-586. PubMed ID: 37696420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the therapeutic potential of SGLT2 inhibitors in cancer treatment: integrating in silico and in vitro investigations.
    Mohite P; Lokwani DK; Sakle NS
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Aug; 397(8):6107-6119. PubMed ID: 38416196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following
    Korkmaz-Icöz S; Kocer C; Sayour AA; Kraft P; Benker MI; Abulizi S; Georgevici AI; Brlecic P; Radovits T; Loganathan S; Karck M; Szabó G
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.
    Shiba K; Tsuchiya K; Komiya C; Miyachi Y; Mori K; Shimazu N; Yamaguchi S; Ogasawara N; Katoh M; Itoh M; Suganami T; Ogawa Y
    Sci Rep; 2018 Feb; 8(1):2362. PubMed ID: 29402900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canagliflozin-loaded magnetic nanoparticles as potential treatment of hypoxic tumors in combination with radiotherapy.
    Angelopoulou A; Kolokithas-Ntoukas A; Papaioannou L; Kakazanis Z; Khoury N; Zoumpourlis V; Papatheodorou S; Kardamakis D; Bakandritsos A; Hatziantoniou S; Avgoustakis K
    Nanomedicine (Lond); 2018 Oct; 13(19):2435-2454. PubMed ID: 30311542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms.
    Osataphan S; Macchi C; Singhal G; Chimene-Weiss J; Sales V; Kozuka C; Dreyfuss JM; Pan H; Tangcharoenpaisan Y; Morningstar J; Gerszten R; Patti ME
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter‑1 and lactate dehydrogenase A.
    Xu D; Zhou Y; Xie X; He L; Ding J; Pang S; Shen B; Zhou C
    Int J Oncol; 2020 Nov; 57(5):1223-1233. PubMed ID: 32901837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antidiabetic SGLT2 inhibitor canagliflozin reduces mitochondrial metabolism in a model of skeletal muscle insulin resistance.
    VanDerStad LR; Wyatt EC; Vaughan RA
    Diabet Med; 2024 May; 41(5):e15271. PubMed ID: 38140911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness in the inhibition of dapagliflozin and canagliflozin on M-type K
    So EC; Liu PY; Wu SN
    Eur J Pharmacol; 2020 Jul; 879():173141. PubMed ID: 32353360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.